Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Diazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 8/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 8/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 8/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 8/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 5/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diazepam SCHEMBL16922183 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL9278054 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL29362687 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL21442 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL3043280 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL11345350 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL6298785 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL6014348 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL17555369 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL4370625 | 0.99 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968129-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2018-09-05 | — | — | EP | claimed |
| US-20030175354-A1 | Antiemetic, anti-motion sustained release drug delivery system | L.A.M. PHARMACEUTICAL CORPORATION (CA) | 2003-09-18 | — | — | US | claimed |
| WO-2003009829-A2 | ANTIEMETIC, ANTI-MOTION SUSTAINED RELEASE DRUG DELIVERY SYSTEM | L.A.M. PHARMACEUTICAL CORPORATION (CA) | 2003-02-06 | — | — | WO | claimed |
| US-20020172712-A1 | Antiemetic, anti-motion sustained release drug delivery system | GLYCOBIOSCIENCES INC. (CA) | 2002-11-21 | — | — | US | claimed |
| CN-115201469-B | Detection device | 艾康生物技术(杭州)有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20220117887-A1 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | NEURELIS, INC. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3415139-A1 | ADMINISTRATION OF BENZODIAZEPINE | Hale Biopharma Ventures, Llc (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-2720699-B1 | ADMINISTRATION OF BENZODIAZEPINE | HALE BIOPHARMA VENTURES LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| WO-2017178682-A1 | COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ALCOHOL USE DISORDERS | SERVICIO ANDALUZ DE SALUD (ES) | 2017-10-19 | — | — | WO | disclosed |
| US-9763876-B2 | Administration of benzodiazepine compositions | HALE BIOPHARMA VENTURES, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170196884-A1 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | NEURELIS, INC. | 2017-07-13 | — | — | US | disclosed |
| EP-3069118-A1 | A DEVICE AND METHOD FOR USING THE DEVICE | Abon Biohparm (Hangzhou) Co., Ltd (CN) | 2016-09-21 | — | — | EP | disclosed |
| EP-0889731-A1 | INJECTABLE THERAPY FOR CONTROL OF MUSCLE SPASMS AND PAIN RELATED TO MUSCLE SPASMS | Allergan Sales, Inc. (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5776783-A | Method of monitoring therapeutic agent consumption | PRIVATE CLINIC LABORATORIES, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998012557-A1 | THERAPEUTIC AGENT WITH QUANTITATIVE CONSUMPTION MARKER AND METHOD OF MONITORING THERAPEUTIC AGENT CONSUMPTION | PRIVATE CLINIC LABORATORIES, INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| WO-1997034624-A1 | INJECTABLE THERAPY FOR CONTROL OF MUSCLE SPASMS AND PAIN RELATED TO MUSCLE SPASMS | ALLERGAN SALES, INC. (US) | 1997-09-25 | — | — | WO | disclosed |
| US-4248999-A | ANTITUMOR AGENTS | SANKYO COMPANY LIMITED (JP) | 1981-02-03 | — | — | US | disclosed |
| US-4087614-A | Optically active 1,4-benzodiazepines intermediates | KAJFEZ FRANJO | 1978-05-02 | — | — | US | disclosed |
| US-4045569-A | Optically active 1,4-benzodiazepines and process for use as a tranquilizer | KAJFEZ FRANJO | 1977-08-30 | — | — | US | disclosed |
| US-3998811-A | SEDATIVES, TRANQUILIZERS; AMIDATION, CYCLIZATION, HYDROLYSIS | CRC COMPAGNIA DI RECERCA CHIMICA S.A. (CH) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196884-A1 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | GABRA5, GABRA6, GABRA3 | GABRA1 5/4885GABRG2 9/4885GABRB3 8/4885 |
| US-20220117887-A1 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | GABRA5, GABRA6, GABRA3 | GABRA1 5/4885GABRG2 9/4885GABRB3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.